Article Text

Download PDFPDF

S6. Proffered paper: Anti-tumour immunomodulatory activity of heat shock protein Hsp70 in therapy of malignant brain tumours: preclinical and clinical data
  1. M Shevtsov1,
  2. A Kim2,
  3. W Khachatryan2,
  4. A Pozdnyakov3,
  5. I Romanova4,
  6. I Guzhova1 and
  7. B Margulis1
  1. Aff1 grid.418947.70000000096293848Institute of Cytology RAS Saint-Petersburg Russian Federation
  2. Aff2 A.L. Polenov Russian Scientific Research Institute of NeurosurgeryPaediatric Neurosurgery Saint-Petersburg Russian Federation
  3. Aff3 City Clinical Oncological DispenserDepartment of Radiology Saint-Petersburg Russian Federation
  4. Aff4 I.M.Sechenov Institute of Evolutionary Physiology and Biochemistry RASDepartment of Morphology Saint-Petersburg Russian Federation

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


Immunotherapy provides a specific anti-tumour activity with minimal side effects and thus could be used in treatment of malignant brain tumours. Molecular chaperone Hsp70 is well known for its ability to stimulate innate and adaptive anti-cancer immune response. In in vivo studies we proved the efficacy of the intratumoral delivery of Hsp70 in the model of intracranial glioma C6 in animals. Based on our preclinical in vivo data we conducted for the first time pilot study for assessment of anti-tumour activity of Hsp70 in patients with brain tumours.

Material and methods

12 patients with diagnosis of malignant brain tumour were enrolled in clinical trial. Following tumour resection protein was infused into tumor cavity. Specific immune response was evaluated in delayed hypersensitivity test (DTH). Peripheral blood was monitored for possible changes in lymphocyte subpopulations cytokine levels and cytolityc activity of NK-cells. Additionally cytokine production was analyzed in dynamics in liquor after injection of Hsp70. All patients were monitored for adverse effects.


Intratumoral injections of Hsp70 were well tolerated in patients. One patient had complete clinical response and one partial response documented by radiological findings. In three patients we observed positive DTH-test. In peripheral blood we observed a shift from cytokines of those provided by Th2-helpers towards cytokines from Th1-mediated response (i.e., INF-gamma, TNF-alpha). This data corresponded to changes in lymphocyte subpopulations. NK-cell activity was not altered.


This pilot study demonstrated for the first time feasibility and safety of intratumoral delivery of recombinant Hsp70 in cancer patients. Based on our preclinical and clinical findings we proposed the novel hypothesis of immunomodulatory mechanism of Hsp70. Our results suggest that purified Hsp70 can induce specific effective anti-tumor immune response and warrants further investigation in randomised clinical trials.